The development of K-RasG12C inhibitors with antitumor activity has demonstrated the feasibility of targeting these previously “undruggable” oncoproteins and showed that KRAS-mutant cancers remain addicted to hyperactive Ras in vivo (1–3). This evidence concerns the gene KRAS and cancer.